Site-specific analysis of the SARS-CoV-2 glycan shield

The emergence of the betacoronavirus, SARS-CoV-2 that causes COVID-19, represents a significant threat to global human health. Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, that mediates cell entry and membrane fusion. SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in immune evasion and occluding immunogenic protein epitopes. Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen. This analysis enables mapping of the glycan-processing states across the trimeric viral spike. We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design.

[1]  B. Hogue,et al.  Coronavirus envelope (E) protein remains at the site of assembly , 2015, Virology.

[2]  Darrell J Irvine,et al.  Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers , 2019, Science.

[3]  John R Yates,et al.  Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer , 2018, Nature Communications.

[4]  Alexis Rohou,et al.  cisTEM: User-friendly software for single-particle image processing , 2017, bioRxiv.

[5]  A. Walls,et al.  Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.

[6]  John P. Moore,et al.  Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer , 2016, Journal of Virology.

[7]  M. Crispin,et al.  Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope , 2015, Journal of Virology.

[8]  S. Perlman,et al.  Coronaviruses: An Overview of Their Replication and Pathogenesis , 2015, Methods in molecular biology.

[9]  Ian A Wilson,et al.  Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. , 2015, Cell reports.

[10]  I. Rudan,et al.  Variability, heritability and environmental determinants of human plasma N-glycome. , 2009, Journal of proteome research.

[11]  M. Ng,et al.  Proliferative growth of SARS coronavirus in Vero E6 cells. , 2003, The Journal of general virology.

[12]  Pauline M Rudd,et al.  Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein , 2010, Virology.

[13]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[14]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[15]  Raymond A. Dwek,et al.  Emerging Principles for the Therapeutic Exploitation of Glycosylation , 2014, Science.

[16]  Silke Stertz,et al.  The intracellular sites of early replication and budding of SARS-coronavirus , 2007, Virology.

[17]  Barney S. Graham,et al.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.

[18]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[19]  Young Do Kwon,et al.  Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G , 2016, Cell.

[20]  K. Khoo,et al.  Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans , 2020, Proceedings of the National Academy of Sciences.

[21]  Andrea Marzi,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[22]  James E. Crowe,et al.  Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus , 2010, Science.

[23]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[24]  I. Wilson,et al.  Exploitation of glycosylation in enveloped virus pathobiology , 2019, Biochimica et Biophysica Acta (BBA) - General Subjects.

[25]  V. Reinhold,et al.  The N-glycome of human plasma. , 2010, Journal of proteome research.

[26]  J. Diedrich,et al.  HIV-1 Envelope Glycoprotein Clone BG505 delCT N332T in complex with broadly neutralizing antibody Fab PGT151 , 2018 .

[27]  R. Desrosiers,et al.  Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding , 2016, Scientific Reports.

[28]  B. Haynes,et al.  The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template , 2019, Cell reports.

[29]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[30]  D. Burton,et al.  Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization , 2018, Immunity.

[31]  Paul Emsley,et al.  Structural analysis of glycoproteins: building N-linked glycans with Coot , 2018, Acta crystallographica. Section D, Structural biology.

[32]  David J. Harvey,et al.  Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen , 2018, Cell reports.

[33]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[34]  Thomas Strecker,et al.  Structure of the Lassa virus glycan shield provides a model for immunological resistance , 2018, Proceedings of the National Academy of Sciences.

[35]  R. Dwek,et al.  Exploiting the defensive sugars of HIV-1 for drug and vaccine design , 2007, Nature.

[36]  Bette Korber,et al.  Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. , 2004, Glycobiology.

[37]  D. Burton,et al.  Unprecedented Role of Hybrid N-Glycans as Ligands for HIV-1 Broadly Neutralizing Antibodies. , 2018, Journal of the American Chemical Society.

[38]  Zachary T. Berndsen,et al.  Vulnerabilities in coronavirus glycan shields despite extensive glycosylation , 2020, Nature Communications.

[39]  Weston B Struwe,et al.  Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein , 2016, Cell reports.

[40]  Chih-Jen Wei,et al.  Cross-Neutralization of 1918 and 2009 Influenza Viruses: Role of Glycans in Viral Evolution and Vaccine Design , 2010, Science Translational Medicine.